These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23773864)

  • 21. Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
    Wang AX; Chen J; Zhao Q; Sun LQ; Friborg J; Yu F; Hernandez D; Good AC; Klei HE; Rajamani R; Mosure K; Knipe JO; Li D; Zhu J; Levesque PC; McPhee F; Meanwell NA; Scola PM
    Bioorg Med Chem Lett; 2017 Feb; 27(3):590-596. PubMed ID: 28011221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
    Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
    Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V
    J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX; Njoroge FG
    Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
    [No Abstract]   [Full Text] [Related]  

  • 29. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
    J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
    Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
    Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
    Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
    [No Abstract]   [Full Text] [Related]  

  • 32. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
    Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG
    J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
    Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease.
    Liu H; Wu R; Sun Y; Ye Y; Chen J; Luo X; Shen X; Liu H
    Bioorg Med Chem; 2014 Nov; 22(22):6344-52. PubMed ID: 25438757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
    Perni RB; Chandorkar G; Cottrell KM; Gates CA; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao G; Schairer WC; Van Drie J; Wei Y
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3406-11. PubMed ID: 17482818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
    Perni RB; Farmer LJ; Cottrell KM; Court JJ; Courtney LF; Deininger DD; Gates CA; Harbeson SL; Kim JL; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao BG; Schairer WC; Tung RD; Van Drie JH; Wilson K; Thomson JA
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1939-42. PubMed ID: 15050632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
    Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
    Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
    Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.
    Matthew AN; Zephyr J; Hill CJ; Jahangir M; Newton A; Petropoulos CJ; Huang W; Kurt-Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2017 Jul; 60(13):5699-5716. PubMed ID: 28594175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.